Literature DB >> 18619619

Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury.

Michael J Guzman1, Paul R Crisostomo, Meijing Wang, Troy A Markel, Yue Wang, Daniel R Meldrum.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a central growth and survival factor for both the endothelium and the myocardium. Recent evidence also suggests that VEGF may play a critical role in stem-cell-mediated paracrine cardioprotection. However, the acute effect of exogenous VEGF on myocardium after ischemia, indeed whether isolated VEGF alone may be a clinically useful therapeutic modality, remains unknown. We hypothesize that infusion of exogenous VEGF immediately prior to ischemia will improve myocardial functional recovery.
MATERIALS AND METHODS: Adult male Sprague Dawley rat hearts were isolated and perfused via Langendorff model. All hearts were subject to 15-min equilibration, 25-min warm global ischemia, and 40-min reperfusion. Experimental hearts received a VEGF infusion of 3 x physiological (13 nM, n = 4), 5x physiological (20 nM, n = 4), or 10x physiological (40 nM, n = 5) immediately prior to ischemia. Controls (n = 5) were infused with perfusate vehicle. Functional indices (left ventricular developed pressure), end diastolic pressure, +/-dP/dt were continuously recorded.
RESULTS: End diastolic pressure (mmHg) was elevated in response to ischemia/reperfusion. However, hearts infused with 10x VEGF demonstrated significantly (P < 0.05, analysis of variance and Bonferroni's) decreased end diastolic pressure throughout reperfusion compared to control (49.82 +/- 10.35 mmHg versus 80.73 +/- 6.08 mmHg at end reperfusion). 10x VEGF-treated hearts also exhibited significantly (P < 0.05, analysis of variance and Bonferroni's) greater recovery of left ventricular developed pressure (69.97 +/- 9.69% versus 39.74 +/- 7.01% of equilibration), +dP/dt, and -dP/dt at end reperfusion. However, neither 3 x nor 5x VEGF improved recovery after ischemia. VEGF also did not influence coronary flow after ischemia.
CONCLUSION: This is the first demonstration that exogenous VEGF administration acutely improves myocardial functional recovery after ischemia. These findings may help elucidate the role of VEGF in acute stem-cell-mediated paracrine effects and suggests that isolated VEGF may be of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619619     DOI: 10.1016/j.jss.2007.12.772

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury.

Authors:  Aaron M Abarbanell; Yue Wang; Jeremy L Herrmann; Brent R Weil; Jeffrey A Poynter; Mariuxi C Manukyan; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

2.  VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function.

Authors:  Troy A Markel; Yue Wang; Jeremy L Herrmann; Paul R Crisostomo; Meijing Wang; Nathan M Novotny; Christine M Herring; Jiangning Tan; Tim Lahm; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-10       Impact factor: 4.733

3.  Are neonatal stem cells as effective as adult stem cells in providing ischemic protection?

Authors:  Troy A Markel; Paul R Crisostomo; Maiuxi C Manukyan; Dalia Al-Azzawi; Christine M Herring; Tim Lahm; Nathan M Novotny; Daniel R Meldrum
Journal:  J Surg Res       Date:  2008-04-28       Impact factor: 2.192

4.  Tongxinluo modulates cytokine secretion by cardiac microvascular endothelial cells in ischemia/reperfusion injury.

Authors:  Hehe Cui; Na Li; Xiangdong Li; Kang Qi; Qing Li; Chen Jin; Tianjie Wang; Lian Duan; Leipei Jiang; Guihao Chen; Zhigang Wang; Cong Wei; Yuejin Yang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 5.  Optimizing stem cell function for the treatment of ischemic heart disease.

Authors:  Jeremy L Herrmann; Aaron M Abarbanell; Brent R Weil; Mariuxi C Manukyan; Jeffrey A Poynter; Benjamin J Brewster; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-06-16       Impact factor: 2.192

6.  Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats.

Authors:  Humann Matori; Soban Umar; Rangarajan D Nadadur; Salil Sharma; Rod Partow-Navid; Michelle Afkhami; Marjan Amjedi; Mansoureh Eghbali
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

7.  Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs.

Authors:  Robert M Osipov; Michael P Robich; Jun Feng; Richard T Clements; Yuhong Liu; Hilary P Glazer; John Wagstaff; Cesario Bianchi; Frank W Sellke
Journal:  J Appl Physiol (1985)       Date:  2009-04-16

8.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

9.  Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation.

Authors:  Vincenzo Lionetti; Silvia Cantoni; Claudia Cavallini; Francesca Bianchi; Sabrina Valente; Irene Frascari; Elena Olivi; Giovanni D Aquaro; Francesca Bonavita; Ignazio Scarlata; Margherita Maioli; Valentina Vaccari; Riccardo Tassinari; Antonietta Bartoli; Fabio A Recchia; Gianandrea Pasquinelli; Carlo Ventura
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

10.  Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor.

Authors:  Nicola C Hunt; Richard M Shelton; Deborah J Henderson; Liam M Grover
Journal:  Tissue Eng Part A       Date:  2012-12-07       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.